Question · Q3 2025
Evan Seiderman asked how the current pipeline needs to mature to drive growth through the Jakafi LOE, what type of business development would supplement that growth, and what Incyte looks like with and without mCALR by the end of the decade.
Answer
CEO Bill Meury outlined seven key drivers: Povorcitinib (three indications, dermatology franchise), 989 (mCALR), 617F (mCALR bispecific, potentially 2X 989's size), three solid tumor programs (KRAS G12D, TGF-beta by PD-1, CDK2), and Naktinvo (two combination trials). He emphasized that not all need to work, but 2-3 hits from these seven could build a business larger than the current one post-2029. He stated he could not exclude mCALR from the picture due to its importance.